Effect of the immunomodulant 2-cyanaziridine derivative BM 41.332 on adjuvant arthritis in the rat.
2-Cyan-1-[(2-methoxy-6-methyl-pyridin-3-yl)-methyl]-aziridine (BM 41.332), a derivative of the immuno-stimulant group of 2-cyanaziridines, showed a therapeutic action in adjuvant arthritis in the rat. Although it does not possess any direct anti-inflammatory action, BM 41.332 showed activity which differed clearly from conventional antirheumatic agents such as cyclophosphamide, glucocorticoids, levamisole or indometacin.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D001168:Arthritis / Q000628:therapy*; D001169:Arthritis, Experimental / Q000473:pathology / Q000628:therapy*; D001388:Aziridines / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D007958:Leukocyte Count; D007978:Levamisole / Q000494:pharmacology; D008297:Male; D008775:Methylprednisolone / Q000494:pharmacology; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors
D000276:Adjuvants, Immunologic; D001388:Aziridines; D001389:Azirines; D007978:Levamisole; C035520:ciamexon; D003520:Cyclophosphamide; D008775:Methylprednisolone; D007213:Indomethacin